The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization

References

• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X28822787
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 Available from: https://goldCOPD.org Accessed 5 31, 2019.
   Google Scholar
• WHO. Chronic Obstructive Pulmonary Disease (COPD): fact sheet. 2017 Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) Accessed 124, 2019.
   Google Scholar
• GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1260–1344. doi:10.1016/S0140-6736(17)32130-X28919118
   PubMed Web of Science ®Google Scholar
• Vasankari TM, Impivaara O, Heliövaara M, et al. No increase in the prevalence of COPD in two decades. Eur Respir J. 2010;36(4):766–773. doi:10.1183/09031936.0017810920693258
   PubMed Web of Science ®Google Scholar
• Kotaniemi J-T, Sovijärvi A, Lundbäck B. Chronic obstructive pulmonary disease in finland: prevalence and risk factors. COPD. 2005;2(3):331–339. doi:10.1080/1541255050021812217146998
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. the Copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC26641631
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Tran TN, Butler RK, et al. Relationship of blood eosinophil count to exacerbations in chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2018;6(3):944–954 e945. doi:10.1016/j.jaip.2017.10.00429153881
   PubMed Web of Science ®Google Scholar
• Rennard S, Decramer M, Calverley PMA, et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of confronting COPD international survey. Eur Respir J. 2002;20(4):799–805. doi:10.1183/09031936.02.0324200212412667
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212–227. doi:10.1177/204062231453286225177479
   PubMedGoogle Scholar
• Johansson G, Mushnikov V, Bäckström T, et al. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med. 2018;18(1):17. doi:10.1186/s12890-018-0573-029370846
   PubMed Web of Science ®Google Scholar
• Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-097225058738
   PubMed Web of Science ®Google Scholar
• Herse F, Kiljander T, Lehtimäki L. Annual costs of chronic obstructive pulmonary disease in Finland during 1996–2006 and a prediction model for 2007–2030. NPJ Prim Care Respir Med. 2015;25:15015. doi:10.1038/npjpcrm.2015.1525811648
   PubMed Web of Science ®Google Scholar
• Barjaktarevic IZ, Arredondo AF, Cooper CB. Positioning new pharmacotherapies for COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1427–1442. doi:10.2147/COPD.S8375826244017
   PubMed Web of Science ®Google Scholar
• Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83. doi:10.1186/1471-2288-11-8321619668
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Ding B, Small M, Bergström G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. Int J Chron Obstruct Pulmon Dis. 2017;12:677–689. doi:10.2147/COPD.S12389628260874
   PubMed Web of Science ®Google Scholar
• Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217. doi:10.18553/jmcp.2019.25.2.20530698096
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE,Locantore N, Agusti A, Tal-Singer R; on behalf of the ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.0016241425323230
   PubMed Web of Science ®Google Scholar
• Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23. doi:10.5588/ijtld.15.047226688525
   PubMed Web of Science ®Google Scholar
• Ortega H, Llanos JP, Lafeuille MH, et al. Burden of disease associated with a COPD eosinophilic phenotype. Int J Chron Obstruct Pulmon Dis. 2018;13:2425–2433. doi:10.2147/COPD.S17099530147308
   PubMed Web of Science ®Google Scholar